诺维苯在晚期NSCLC化疗中的应用价值

目的观察诺维苯在晚期NSCLC化疗中的疗效和毒性反应情况。方法收集晚期非小细胞肺癌46例，以诺维苯作为一个主要化疗药物并联合应用既往被证实对NSCLC有确切疗效的顺铂组方进行化疗，NVB25mg/m

Clinical Study of Navelbine in Advanced Non-small Cell Lung Cancer

Objective：To observe the efficacy and toxicity of Navelbine in advanced non-small cell lung cancer.Methods：To collect 46 cases of the advanced non-small cell lung cancer,which was treated by main chemotherapy of Navelbine for two cycles,then to evaluate the efficacy and toxicity,visit the relievable and existing period.Results：Among this group of 46 cases patients,the total efficacy is 39.1%.The one of first cases is 40.7%,the one of return cases is 36.8%,they have no marked difference (P＞0.05).The middle relievable period is five months.The major toxicity is bone marrow restrain,phlebitis and peripheral neuritis,especially affected WBC and PLT.Conclusion：Navelbine is a sort of new good anti-cancer drug to treat the advanced non-small cell lung cancer and has more satisfied efficacy,the toxicity is able to bear,if G-csf is used to defend and treat the serious bone marrow restrain,it will have better prospective.